Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- Prostate Cancer
- Registration Number
- NCT00003238
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different way to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic prostate cancer that has not responded to hormone therapy with androgens.
- Detailed Description
OBJECTIVES: I. Evaluate the clinical effectiveness of oral perillyl alcohol given to patients with androgen independent metastatic prostate cancer. II. Assess the toxicity of this treatment in these patients.
OUTLINE: Patients receive oral perillyl alcohol 4 times a day for 4 weeks. Patients continue treatment in the absence of severe toxicity and disease progression. Patients are followed every 3 months for survival after disease progression.
PROJECTED ACCRUAL: This study will accrue 20-40 patients in approximately 2 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Leonard C. Ferguson Cancer Center
🇺🇸Freeport, Illinois, United States
Gundersen Lutheran Medical Center
🇺🇸La Crosse, Wisconsin, United States
Green Bay Oncology, Ltd.
🇺🇸Green Bay, Wisconsin, United States
Mercy Health System
🇺🇸Janesville, Wisconsin, United States
Meriter Hospital
🇺🇸Madison, Wisconsin, United States
North Central Oncology Associates, S.C.
🇺🇸Wausau, Wisconsin, United States
University of Wisconsin Comprehensive Cancer Center
🇺🇸Madison, Wisconsin, United States
Sinai Samaritan Medical Center - Milwaukee
🇺🇸Milwaukee, Wisconsin, United States